Ahmad Al-Khatib, MD
Neurology · Bentonville, ARNPI 1548273394
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 31.7% of the total. Reporting peaked in 2021 at $9,861 and has fallen 76.6% since, to $2,310 in 2025. Among neurology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 857 payments — averaging $34.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Biohaven Pharmaceuticals, Inc.$5K
- Biohaven Pharmaceutical Holding Company Ltd.$4K
- Biogen$1K
- UCB, Inc.$868
- Novartis$662
- plus $9K from 54 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$14,82850%
- Travel & lodging$1,0834%
- Food & beverage$13,55046%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$8,498
- UBRELVY$7,641
- TYSABRI$150
- QULIPTA$121
How this compares
$29,732 in reported general payments places this provider in the 90th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 65 | $348,893 |
| CopaxoneGlatiramer Acetate | 26 | $149,037 |
| VumerityDiroximel Fumarate | 14 | $120,867 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $115,038 |
| AubagioTeriflunomide | 11 | $103,642 |
| Kesimpta PenOfatumumab | 11 | $94,550 |
| Teriflunomide | 58 | $83,950 |
| Lamictal XrLamotrigine | 13 | $70,368 |
| FycompaPerampanel | 55 | $55,505 |
| Aimovig AutoinjectorErenumab-Aooe | 38 | $36,689 |
| UbrelvyUbrogepant | 32 | $34,683 |
| Emgality PenGalcanezumab-Gnlm | 29 | $27,824 |
| GlatopaGlatiramer Acetate | 13 | $25,005 |
| Glatiramer Acetate | 14 | $22,359 |
| Nurtec OdtRimegepant Sulfate | 19 | $21,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $106 | $348,89365 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $356 | $149,03726 claims |
| BiogenVumerity | $1,271 | $120,86714 claims |
| SanofiAubagio | $523 | $103,64211 claims |
| AbbVieUbrelvy, Botox, Qulipta | $9,428 | $78,14769 claims |
| Eisai Inc.Fycompa | $600 | $55,50555 claims |
| SandozGlatopa | $30 | $25,00513 claims |
| PfizerNurtec Odt | $413 | $21,93519 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $241 | $4,38260 claims |
| Upsher-smith Laboratories LLCTopiramate | $118 | $2,978312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 neurology providers in Arkansas.
Other neurology in Bentonville
- Kathryn ChenaultSherwood$532K
- Steve-Felix BelingaFort Smith$183K
- Michael MorseFayetteville$149K
- Mark PippengerNorth Little Rock$109K
- Kara WayHot Springs$72K
- Keith SchlutermanConway$67K
- Shitiz SriwastavaLittle Rock$59K
- Ronald SouthJonesboro$59K
- Elizabeth SullivanLittle Rock$33K
- Timothy FreyaldenhovenConway$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.